4
|
Jansen RW, de Bloeme CM, Cardoen L, Göricke S, van Elst S, Jessen JL, Ramasubramanian A, Skalet AH, Miller AK, Maeder P, Uner OE, Hubbard GB, Grossniklaus H, Boldt HC, Nichols KE, Brennan RC, Sen S, Sirin S, Brisse HJ, Galluzzi P, Dommering CJ, Castelijns JA, van der Valk P, Boellaard R, Dorsman J, Moll AC, de Jong MC, de Graaf P. MRI Features for Identifying MYCN-amplified RB1 Wild-type Retinoblastoma. Radiology 2023; 307:e222264. [PMID: 37191489 PMCID: PMC10315525 DOI: 10.1148/radiol.222264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 03/06/2023] [Accepted: 03/20/2023] [Indexed: 05/17/2023]
Abstract
Background MYCN-amplified RB1 wild-type (MYCNARB1+/+) retinoblastoma is a rare but clinically important subtype of retinoblastoma due to its aggressive character and relative resistance to typical therapeutic approaches. Because biopsy is not indicated in retinoblastoma, specific MRI features might be valuable to identify children with this genetic subtype. Purpose To define the MRI phenotype of MYCNARB1+/+ retinoblastoma and evaluate the ability of qualitative MRI features to help identify this specific genetic subtype. Materials and Methods In this retrospective, multicenter, case-control study, MRI scans in children with MYCNARB1+/+ retinoblastoma and age-matched children with RB1-/- subtype retinoblastoma were included (case-control ratio, 1:4; scans acquired from June 2001 to February 2021; scans collected from May 2018 to October 2021). Patients with histopathologically confirmed unilateral retinoblastoma, genetic testing (RB1/MYCN status), and MRI scans were included. Associations between radiologist-scored imaging features and diagnosis were assessed with the Fisher exact test or Fisher-Freeman-Halton test, and Bonferroni-corrected P values were calculated. Results A total of 110 patients from 10 retinoblastoma referral centers were included: 22 children with MYCNARB1+/+ retinoblastoma and 88 control children with RB1-/- retinoblastoma. Children in the MYCNARB1+/+ group had a median age of 7.0 months (IQR, 5.0-9.0 months) (13 boys), while children in the RB1-/- group had a median age of 9.0 months (IQR, 4.6-13.4 months) (46 boys). MYCNARB1+/+ retinoblastomas were typically peripherally located (in 10 of 17 children; specificity, 97%; P < .001) and exhibited plaque or pleomorphic shape (in 20 of 22 children; specificity, 51%; P = .011) with irregular margins (in 16 of 22 children; specificity, 70%; P = .008) and extensive retina folding with vitreous enclosure (specificity, 94%; P < .001). MYCNARB1+/+ retinoblastomas showed peritumoral hemorrhage (in 17 of 21 children; specificity, 88%; P < .001), subretinal hemorrhage with a fluid-fluid level (in eight of 22 children; specificity, 95%; P = .005), and strong anterior chamber enhancement (in 13 of 21 children; specificity, 80%; P = .008). Conclusion MYCNARB1+/+ retinoblastomas show distinct MRI features that could enable early identification of these tumors. This may improve patient selection for tailored treatment in the future. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Rollins in this issue.
Collapse
Affiliation(s)
- Robin W. Jansen
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Christiaan M. de Bloeme
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Liesbeth Cardoen
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Sophia Göricke
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Sabien van Elst
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Jaime Lyn Jessen
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Aparna Ramasubramanian
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Alison H. Skalet
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Audra K. Miller
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Philippe Maeder
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Ogul E. Uner
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - G. Baker Hubbard
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Hans Grossniklaus
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - H. Culver Boldt
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Kim E. Nichols
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Rachel C. Brennan
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Saugata Sen
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Selma Sirin
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Hervé J. Brisse
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Paolo Galluzzi
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Charlotte J. Dommering
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Jonas A. Castelijns
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Paul van der Valk
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Ronald Boellaard
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Josephine Dorsman
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Annette C. Moll
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Marcus C. de Jong
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| | - Pim de Graaf
- From the Departments of Radiology and Nuclear Medicine (R.W.J.,
C.M.d.B., S.v.E., J.A.C., R.B., M.C.d.J., P.d.G.), Human Genetics (C.J.D.),
Pathology (P.v.d.V.), Oncogenetics (J.D.), and Ophthalmology (A.C.M.), Amsterdam
University Medical Center, Vrije Universiteit, Office PK-1X012, De Boelelaan
1117, 1081 HV Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam,
the Netherlands (R.W.J., C.M.d.B., S.v.E., J.D., A.C.M., M.C.d.J., P.d.G.);
European Retinoblastoma Imaging Collaboration (R.W.J., C.M.d.B., L.C., S.G.,
P.M., H.C.B., P.G., J.A.C., M.C.d.J., P.d.G.); Imaging Department, Institut
Curie Paris, Paris, France (L.C., H.J.B.); Institute of Diagnostic and
Interventional Radiology and Neuroradiology, University Hospital Essen, Essen,
Germany (S.G.); Impact Genetics–Dynacare, Brampton, Canada (J.L.J.);
Department of Ophthalmology, Phoenix Children’s Hospital, Phoenix, Ariz
(A.R.); Casey Eye Institute & Knight Cancer Institute, Oregon Health
& Science University, Portland, Ore (A.H.S., A.K.M.); Department of
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
(P.M.); Department of Ophthalmology, Casey Eye Institute, Oregon Health &
Science University, Portland, Ore (O.E.U.); Ocular Oncology Service, Emory Eye
Center, Atlanta, Ga (O.E.U., G.B.H., H.G.); Department of Ophthalmology,
University of Iowa Hospitals & Clinics, Iowa City, Iowa (H.C.B.);
Department of Oncology, St Jude Children’s Research Hospital, Memphis,
Tenn (K.E.N., R.C.B.); Department of Pediatric Hematology/Oncology, Logan
Health, Kalispell, Mont (R.C.B.); Department of Radiology and Imaging Sciences,
Tata Medical Center, Kolkata, India (S. Sen); Department of Diagnostic Imaging,
University Children’s Hospital Zürich, Zürich, Switzerland
(S. Sirin); and Azienda Ospedaliera Universitaria Senese, Siena, Italy
(P.G.)
| |
Collapse
|
15
|
Jansen RW, de Jong MC, Kooi IE, Sirin S, Göricke S, Brisse HJ, Maeder P, Galluzzi P, van der Valk P, Cloos J, Eekhout I, Castelijns JA, Moll AC, Dorsman JC, de Graaf P. MR Imaging Features of Retinoblastoma: Association with Gene Expression Profiles. Radiology 2018; 288:506-515. [PMID: 29714679 DOI: 10.1148/radiol.2018172000] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Purpose To identify associations between magnetic resonance (MR) imaging features and gene expression in retinoblastoma. Materials and Methods A retinoblastoma MR imaging atlas was validated by using anonymized MR images from referral centers in Essen, Germany, and Paris, France. Images were from 39 patients with retinoblastoma (16 male and 18 female patients [the sex in five patients was unknown]; age range, 5-90 months; inclusion criterion: pretreatment MR imaging). This atlas was used to compare MR imaging features with genome-wide messenger RNA (mRNA) expression data from 60 consecutive patients obtained from 1995 to 2012 (35 male patients [58%]; age range, 2-69 months; inclusion criteria: pretreatment MR imaging, genome-wide mRNA expression data available). Imaging pathway associations were analyzed by means of gene enrichment. In addition, imaging features were compared with a predefined gene expression signature of photoreceptorness. Statistical analysis was performed with generalized linear modeling of radiology traits on normalized log2-transformed expression values. P values were corrected for multiple hypothesis testing. Results Radiogenomic analysis revealed 1336 differentially expressed genes for qualitative imaging features (threshold P = .05 after multiple hypothesis correction). Loss of photoreceptorness gene expression correlated with advanced stage imaging features, including multiple lesions (P = .03) and greater eye size (P < .001). The number of lesions on MR images was associated with expression of MYCN (P = .04). A newly defined radiophenotype of diffuse-growing, plaque-shaped, multifocal tumors displayed overexpression of SERTAD3 (P = .003, P = .049, and P = .06, respectively), a protein that stimulates cell growth by activating the E2F network. Conclusion Radiogenomic biomarkers can potentially help predict molecular features, such as photoreceptorness loss, that indicate tumor progression. Results imply a possible role for radiogenomics in future staging and treatment decision making in retinoblastoma.
Collapse
Affiliation(s)
- Robin W Jansen
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Marcus C de Jong
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Irsan E Kooi
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Selma Sirin
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Sophia Göricke
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Hervé J Brisse
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Philippe Maeder
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Paolo Galluzzi
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Paul van der Valk
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Jacqueline Cloos
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Iris Eekhout
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Jonas A Castelijns
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Annette C Moll
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Josephine C Dorsman
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| | - Pim de Graaf
- From the Departments of Radiology and Nuclear Medicine (R.W.J., M.C.d.J., J.A.C., P.d.G.), Clinical Genetics (I.E.K., J.C.D.), Ophthalmology (A.C.M.), Pathology (P.v.d.V.), Pediatric Oncology (J.C.), and Epidemiology and Biostatistics (I.E.), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; European Retinoblastoma Imaging Collaboration (ERIC) (R.W.J., M.C.d.J., S.S., S.G., H.J.B., P.M., P.G., J.A.C., P.d.G.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany (S.S., S.G.); Department of Radiology, Institut Curie, Paris, France and Paris Sciences et Lettres Research University, Paris, France (H.J.B.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland (P.M.); and Unit of Neuroimaging and Neurointervention, Department of Neurosciences, Siena University Hospital, Siena, Italy (P.G.)
| |
Collapse
|